Comparative Pharmacology
Head-to-head clinical analysis: EMERPHED versus PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMERPHED versus PSEUDOEPHEDRINE HYDROCHLORIDE.
EMERPHED vs PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Terminal elimination half-life: 5-8 hours in adults with normal renal function, prolonged in renal impairment (up to 16-20 hours in severe impairment)
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Renal: 70-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%; biliary: minimal
Category C
Category A/B
Sympathomimetic
Sympathomimetic